drugset / Trial / NCT05350956
A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia
Phase 2
Unknown
60 enrolled
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to confirm the safety and efficacy of Herombopag in tumors-associated thrombocytopenia
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAFUTROMBOPAG | Other / unclassified | 5 mg | Oral |
| Subject | RAFUTROMBOPAG | Other / unclassified | 7.5 mg | Oral |
| Subject | Recombinant Human Thrombopoietin | Protein / enzyme biologic | 300 iu/kg | — |
| Subject | Recombinant Human Thrombopoietin | Protein / enzyme biologic | 15000 iu | — |